Sloan-Kettering Institute For Cancer Research, a non-profit organization, was awarded a $1,408,844 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). This 4-year grant funds research to characterize the theranostic (diagnostic and therapeutic) potential of delta-like ligand 3 (DLL3)-targeting agents for the treatment of high-grade neuroendocrine carcinomas of the lung (small cell lung cancer) and prostate. The research aims to evaluate a DLL3-targeted radiolabeled monoclonal antibody for non-invasive PET imaging diagnosis as well as targeted radiotherapy. The study will assess the safety and efficacy of this novel DLL3-targeted radiotheranostic approach in patients with these aggressive, difficult-to-treat cancers.
Generated 2/25/25, 2:47 AM